Clinical Trial Update: Study of a Progestin to Prevent Bleeding Associated With Initiation of Medical Menopause With GnRH Agonist [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial evaluating a progestin to prevent bleeding during initiation of GnRH agonist–induced medical menopause was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dysfunctional Uterine Bleeding

Drugs mentioned

• Progestin (Progestin)

Snippet

Sponsor: Kaiser Permanente | Conditions: Dysfunctional Uterine Bleeding | Phase 4 | Status: TERMINATED